Aniridia
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 programMorcher iris diaphragm implantationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PTC TherapeuticsAtaluren
PTC TherapeuticsAtaluren
Angeles TherapeuticsMorcher iris diaphragm implantation
Clinical Trials (3)
Total enrollment: 111 patients across 3 trials
A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia
Start: Dec 2018Est. completion: Jan 20210
Phase 2Withdrawn
Study of Ataluren in Participants With Nonsense Mutation Aniridia
Start: Jan 2016Est. completion: Jan 202139 patients
Phase 2Completed
Clinical Evaluation of Morcher Artificial Iris Diaphragms
Start: Apr 2003Est. completion: Dec 202172 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.